Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
62 hedge funds and large institutions have $29.7M invested in Rubius Therapeutics, Inc in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 26 reducing their positions, and 20 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less funds holding
Funds holding: 72 → 62 (-10)
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
55% less capital invested
Capital invested by funds: $66.6M → $29.7M (-$36.9M)
65% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$408K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$193K |
| 3 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
+$143K |
| 4 |
BlackRock
New York
|
+$121K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$38.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$1.88M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.24M |
| 3 |
AFM
Abbot Financial Management
Andover,
Massachusetts
|
-$717K |
| 4 |
Two Sigma Investments
New York
|
-$564K |
| 5 |
Renaissance Technologies
New York
|
-$523K |
RUBY Hedge Fund Activity: Q3 2022 in Review
62 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q3 2022, worth a combined $29.7M — down 55% from $66.6M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of RUBY and 10 opened new positions — a net loss of 10 holders — while 26 trimmed existing stakes and 9 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $408K. The largest seller was Capital World Investors, exiting entirely with an estimated $1.88M sold.
- 62 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q3 2022, down from 72 in Q2 2022.
- Funds reported $29.7M of Rubius Therapeutics, Inc stock for Q3 2022, down 55% quarter-over-quarter.
- 10 funds opened new Rubius Therapeutics, Inc positions in Q3 2022 and 20 closed out, a net change of -10 holders.
- The largest Rubius Therapeutics, Inc buyer in Q3 2022 was Jacobs Levy Equity Management, an estimated $408K added.
- The largest Rubius Therapeutics, Inc seller in Q3 2022 was Capital World Investors, an estimated $1.88M sold.
Based on aggregated 13F filings for Q3 2022.